Update on pediatric liver transplantation in Europe 2022: An ELITA-ESPGHAN report.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Junge Norman, Karam Vincent, Hartog Hermien, Adam Rene, Cailliez Valérie, Indolfi Giuseppe, Samyn Marianne, Stephenne Xavier, Pop Tudor Lucian, Waisbourd-Zinman Orit, Kohlmaier Benno, Zellos Aglaia, Mancell Sara, Gonzales Emmanuel, Nicastro Emanuele, Quintero Jesus, Richter Nicolas, Heaton Nigel, Reding Raymond, Branchereau Sophie, Gupte Girish, Schmelzle Moritz, Fischer Lutz, Kalicinski Piotr, Colledan Michele, Santamaria Manuel Lopez, de Kleine Ruben H, Fitzpatrick Emer, European Liver and Intestine Transplant Association (ELITA) and European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)
Аннотация
METHODS: Data were obtained from ELTR and Eurotransplant (ET). Summary statistics were performed.
RESULTS: In 2022, 585 pLTs were performed in Europe. The annual number of pLT decreased for the third consecutive year. Living donor LT represented 34% (n = 201) of pLT. The proportion of living donation (LD) remained stable over time. The major indication for pLT in Europe is biliary atresia. Donor age is increasing overall and is associated with worse graft survival. Graft and patient survival were impacted by both types of donors and types of grafts, and were significantly worse after re-transplantation. Most graft failures (77%) and deaths (82%) occurred within the first 6 months after pLT.
CONCLUSION: Annual numbers of pLT in Europe are decreasing over time. Given that the proportion of LD has remained stable, the shortage of deceased donor organs may not be the major reason for this trend, and other factors play a role. A focus on improving perioperative care is needed because the risk of graft loss and mortality is highest in the first 6 months after transplantation. New techniques like ex-situ machine perfusion may help mitigate risks with declining quality of deceased donor liver grafts.